ライフサイエンスコーパス: dysphoric

1 e increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/ne

2 ppa opioid receptor (KOR) system encodes the dysphoric component of the stress response and controls

3 allopregnanolone in women with premenstrual dysphoric disorder (PMDD) and in asymptomatic control wo

4 in healthy women and those with premenstrual dysphoric disorder (PMDD) and that a menstrual cycle pha

5 te evidence for the validity of premenstrual dysphoric disorder (PMDD) and the inclusion of the disor

6 is substantial information that premenstrual dysphoric disorder (PMDD) is a clinically significant di

7 tric illnesses tested, although premenstrual dysphoric disorder (PMDD) may be an exception.

8 Premenstrual dysphoric disorder (PMDD) symptoms are eliminated by ova

9 are efficacious treatments for premenstrual dysphoric disorder (PMDD) when given daily or for half o

10 mood and behavioral symptoms in premenstrual dysphoric disorder (PMDD), a common, recently recognized

11 se women also meet criteria for premenstrual dysphoric disorder (PMDD).

12 epilepsy and enhance anxiety in premenstrual dysphoric disorder (PMDD).

13 Patients with premenstrual dysphoric disorder (whose symptoms had remitted during t

14 led protocol to nine women with premenstrual dysphoric disorder and 11 healthy female volunteers in t

15 were measured in 27 women with premenstrual dysphoric disorder and 21 comparison women during the th

16 Women with premenstrual dysphoric disorder and a past history of major depressiv

17 h major depression, and 10 with premenstrual dysphoric disorder and in 34 normal comparison subjects.

18 ts to examine the literature on premenstrual dysphoric disorder and provide recommendations regarding

19 icipation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200 women comple

20 Premenstrual dysphoric disorder appears to be associated with seroton

21 anic disorder and patients with premenstrual dysphoric disorder are highly susceptible to CO(2)-induc

22 In women with premenstrual dysphoric disorder but no past major depressive disorder

23 s of serotonergic deficiency in premenstrual dysphoric disorder by measuring the prolactin response t

24 The patients with premenstrual dysphoric disorder experienced a return of symptoms 24 h

25 normal subjects, the women with premenstrual dysphoric disorder had a significantly blunted prolactin

26 icacy for premenstrual syndrome/premenstrual dysphoric disorder is a general or more serotonergic eff

27 Premenstrual dysphoric disorder is an important cause of symptoms and

28 Premenstrual dysphoric disorder is often associated with major depres

29 d a state-dependent decrease in premenstrual dysphoric disorder might imply a possible continuum betw

30 he panic rate for patients with premenstrual dysphoric disorder was similar to that for panic disorde

31 to determine whether women with premenstrual dysphoric disorder with or without prior major depressiv

32 posttraumatic stress disorder, premenstrual dysphoric disorder, and social phobia.

33 or depression and patients with premenstrual dysphoric disorder, respectively).

34 Premenstrual dysphoric disorder, which affects 2%-5% of premenopausal

35 ch as postpartum depression and premenstrual dysphoric disorder.

36 efficacy of SSRI treatment for premenstrual dysphoric disorder.

37 nhibitors (SSRIs) in women with premenstrual dysphoric disorder.

38 evere premenstrual syndrome and premenstrual dysphoric disorder.

39 involved in the pathogenesis of premenstrual dysphoric disorder.

40 th the observation of an association between dysphoric disorders of epilepsy and POE described nearly

41 ween subtypes of depressive and premenstrual dysphoric disorders.

42 nd to be an important site of action for the dysphoric effects of dynorphin-kappa-opioid receptor sys

43 signaling results in analgesia, whereas the dysphoric effects of KOR agonists are mediated by a diff

44 this endogenous opioid peptide mediates the dysphoric effects of marijuana.

45 y been revived by studies showing that their dysphoric effects require arrestin recruitment, whereas

46 ignaling may be effective analgesics lacking dysphoric effects.

47 ns analysis of participants who had a single dysphoric episode, and they were replicated in an indepe

48 ted that no adverse life events caused their dysphoric episodes reported fatigue, appetite gain, and

49 Practically, our account of how shared dysphoric experiences produce identity fusion helps us b

50 Dysphoric features are statistically salient in patients

51 e that varenicline and cytisine diminish the dysphoric-like state associated with nicotine withdrawal

52 In this view, dysphoric mania is associated with paranoid-destructive

53 s and may be a clinical marker for recurrent dysphoric mania.

54 tidepressants during bipolar mixed states or dysphoric manias.

55 pressive mixed states (mixed depression) and dysphoric (mixed) hypomania (opposite polarity symptoms

56 Depressive or dysphoric-mixed episodes were more prevalent in pregnant

57 st that persistent mood symptoms and overall dysphoric mood are associated with the early perimenopau

58 crease a woman's vulnerability to an overall dysphoric mood during the early perimenopausal period.

59 the changing hormonal milieu contributes to dysphoric mood during transition to menopause.

60 ponse in terms of perceptual alterations and dysphoric mood relative to those without such a family h

61 ore symptoms of hypothyroidism (P<0.001) and dysphoric mood states (P<0.001) after withdrawal of thyr

62 anning is associated with fewer symptoms and dysphoric mood states.

63 ect of being early perimenopausal on overall dysphoric mood was greatest among women with an educatio

64 Depressive symptoms, particularly dysphoric mood, presage future cognitive losses among el

65 Five independent factors representing dysphoric mood, psychomotor pressure, psychosis, increas

66 features of mania and 5 features related to dysphoric mood.

67 such as early alcohol or nicotine use, early dysphoric or anhedonic mood, conduct disorder, and child

68 ssified as classic (predominately euphoric), dysphoric, or depressed.

69 y of patients best characterized as having a dysphoric personality constellation.

70 Kappa-opioid receptor (KOR) agonists have dysphoric properties in humans and are aversive in roden

71 Here, we report that the dysphoric properties of chronic stress are encoded by th

72 ime elapses after trauma, fear circuitry and dysphoric PTSD symptoms appear to emerge as connected ne

73 Elevations in ICSS thresholds reflect a dysphoric state and a lowering of thresholds is indicati

74 melancholia report a distinct and intrusive dysphoric state during internally generated thought.

75 isorder, especially for early depressive and dysphoric states.

76 iated transcription within the NAc regulates dysphoric states.

77 ink between cocaine-cue responses and normal dysphoric states.

78 s on medication also had fewer fixations for dysphoric stimuli compared with depressed participants n

79 healthy volunteers and resolution of chronic dysphoric symptoms in depressed patients were examined w

80 different mechanisms underlie cognitive and dysphoric symptoms in nondemented patients with Parkinso

81 sed transdiagnostic treatments for loss (ie, dysphoric) symptoms.

82 d with scores on mnemonic, visuospatial, and dysphoric tests.

83 assessing selective attention for positive, dysphoric, threatening, and neutral stimuli in addition